Chantal Mathieu is Professor of Medicine at the Katholieke Universiteit Leuven, Belgium. She is Chair of Endocrinology at the University Hospital Gasthuisberg Leuven. Prof Mathieu received her medical degree and PhD at the University of Leuven, where she subsequently completed training in internal medicine and endocrinology. Prof Mathieu’s clinical areas of interest include the organization of diabetes care, and she is involved in several clinical trials in type 1 and type 2 diabetes. Her basic research is focused on the prevention of type 1 diabetes, effects of vitamin D on the immune system and diabetes, and functioning of the insulin-producing beta cell. Prof Mathieu has authored or co-authored more than 400 peer-reviewed publications in international journals. In 2013, Prof Mathieu received the InBev-Baillet Latour Prize for Clinical Research for her pioneering research on the pathogenesis of type 1 diabetes. She presently coordinates the INNODIA project on prevention and intervention in type 1 diabetes in Europe. She is Chair of the European Diabetes Forum and is senior vice-president of EASD and Chair of Postgraduate Education at EASD.
Dualities of interest: Chantal Mathieu has served on advisory panels, has been a speaker or received research support from Adocia, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Dianax, Eli Lilly, GSK, Intrexon, Janssen Pharmaceuticals, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics and Sanofi.